FALSE000202870700020287072026-11-182026-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 18, 2026
MERLIN, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
| Delaware | | 001-42392 | | 98-1797826 |
| (State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
100 Causeway St., Floor 23
Boston, MA 02114
(Address of principal executive offices) (Zip Code)
(857) 201-3979
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share | | MRLN | | The Nasdaq Stock Market LLC (Nasdaq Global Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 18, 2026 (the “Effective Date”), Mr. Matthew George transitioned from serving as the Chief Executive Officer of Merlin, Inc. (“Merlin” or the “Company”) and the Chairman and a member of the Board of Directors of the Company (the “Board”) to the role of Founder and Advisor. In connection with the transition, the Board appointed Dr. Robert H. Smith as Interim Chief Executive Officer and Chairman of the Board. The Board is commencing a search for a permanent CEO and will consider both internal and external candidates.
Biographical Information of Dr. Robert H. Smith
Dr. Smith, age 62, has served as a member of the Board since March 16, 2026. In addition, he has held the roles of Principal at Right Hand Side, a consulting group, and Co-Founder at JATO Foundation since January 2024. Dr. Smith also currently serves as a Senior Advisor to the Office of the Secretary of Defense as part of the Business Operators for National Defense (BOND) program. Prior to that, Dr. Smith was the Chief Executive Officer of Blue Origin, a space startup, from September 2017 until January 2024. Dr. Smith also held various leadership roles in the aerospace industry prior to joining Blue Origin, including at Honeywell Aerospace — where he served in various roles from July 2004 to August 2017 including Chief Technology Officer & President of Mechanical Systems & Components, as well as other roles at United Space Alliance and The Aerospace Corporation. Dr. Smith also currently serves as a director of Parsons Corporation (NYSE: PSN), a role he has held since April 2024 and as an independent director Seurat Technologies, an additive manufacturing company. Dr. Smith holds a bachelor’s degree from Texas A&M in Aerospace Engineering, a master’s degree from Brown in Applied Math and Engineering, a master’s degree from the MIT Sloan School of Management and a Ph.D. in Aerospace Engineering from The University of Texas at Austin.
There are no arrangements or understandings between Dr. Smith and any other person pursuant to which Dr. Smith was selected as Interim Chief Executive Officer, other than with directors or officers of the Company acting solely in those capacities. There are no family relationships between Dr. Smith and any director or executive officer of the Company or person nominated or chosen for either role. Dr. Smith has no direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K.
Transition Agreement with Mr. Matthew George
On November 18, 2026, in connection with Mr. George’s transition from Chief Executive Officer and Chairman and member of the Board to the role of Founder and Advisor, the Company entered into a Transition Agreement with Mr. George (the “Transition Agreement”) that sets forth the terms of Mr. George’s Founder and Advisor role and the amounts payable to Mr. George in connection with the conclusion of his employment as Chief Executive Officer. Mr. George will serve as Founder and Advisor until the first anniversary of the Effective Date, unless earlier terminated by Mr. George for any reason or by the Company for cause. As an independent consultant, Mr. George will receive a monthly fee of $6,250 (pro-rated for partial months) and, at the reasonable request of the Company, will assist in the orderly transition of his duties and responsibilities to such other persons as the Company designates and will provide advice to the Board when and as reasonably requested by the Board and agreed to by Mr. George.
Mr. George’s transition from Chief Executive Officer and Chairman and member of the Board constitutes a resignation for “Good Reason” under the Company’s Executive Severance Plan (the “Severance Plan”). The Transition Agreement provides:
•Mr. George will receive (i) a cash payment equal to one and one-half times his current base salary, paid in eighteen monthly installments, (ii) a 2026 annual bonus, based on target performance and paid in a lump sum following the sixtieth (60th) day after the Effective Date, (iii) eighteen months of subsidized health insurance payments, and (iv) if a Change in Control (as defined in the Severance Plan) occurs (A) on or prior to the third anniversary of the Effective Date, an additional cash payment equal to an additional six months of base salary plus one times his target annual bonus, and (B) on or prior to the first anniversary of the Effective Date, the value of an additional six months of subsidized health insurance; and
•Mr. George’s outstanding options and time-based restricted stock unit awards will continue to vest under the terms of the applicable award agreements and equity incentive plans during the time he serves as Founder and Advisor and, (i) upon termination of Mr. George’s service as Founder and Advisor for any reason other than a termination by the Company for cause or a termination by Mr. George prior to the first anniversary of the Effective Date other than as a result of the Company’s material breach of the Transition Agreement, each then unvested option and restricted stock unit award will become vested and, with respect to the options, exercisable, (ii) if Mr. George
terminates his service prior to the first anniversary of the Effective Date other than as a result of the Company’s material breach of the Transition Agreement, the portion of each award that would have vested through such first anniversary will become vested and, with respect to options, exercisable, or (iii) if a Change of Control occurs on or prior to the first anniversary of the Effective Date, Mr. George’s then-outstanding and unvested equity awards will vest in full.
The Transition Agreement includes non-compete, non-solicit of employees and non-interference with business restrictions, in each case, for the duration of Mr. George’s service as Founder and Advisor, and a standstill agreement for three years following the Effective Date. Mr. George’s service as Founder and Advisor and the above payments and benefits provided to Mr. George pursuant to the Transition Agreement are conditioned on his execution and nonrevocation of a release of claims in favor of the Company and such payments and benefits are also conditioned on his compliance with the terms of the Transition Agreement.
The foregoing summary is qualified in its entirety by reference to the Transition Agreement, which is attached as Exhibit 10.1 to this current report on Form 8-K and which is incorporated by reference into this Item 5.02 and will be filed as an exhibit to the Company’s Form 10-K for the fiscal year ending December 31, 2026.
Offer Letter for Dr. Robert H. Smith
On November 18, 2026, the Company and Dr. Smith entered into a letter agreement (the “Offer Letter”) establishing Dr. Smith’s compensation as Interim Chief Executive Officer of the Company. Dr. Smith’s service as Interim Chief Executive Officer will continue for six months, subject to extension for successive three-month periods on mutual agreement, and will conclude on the first to occur of (a) the date a permanent successor Chief Executive Officer is appointed by the Board, (b) the conclusion of the initial term or a successive term without mutual agreement to continue, or (c) resignation or termination for any reason.
Under the Offer Letter, Dr. Smith’s compensation will consist of a monthly salary of $48,000, prorated for partial months. As additional compensation, Dr. Smith will receive two restricted stock unit awards: (i) an award for 500,000 shares (the “Interim CEO RSU Award”), which will vest on the earlier of the six-month anniversary of the Effective Date or the date Dr. Smith’s service as Interim Chief Executive Officer concludes, so long as such conclusion is not the result of a termination by the Company for cause or an early resignation by Dr. Smith, and (ii) an award for 1,500,000 shares (the “Additional RSU Award”) which will vest in twelve monthly installments, so long as Dr. Smith continues to serve as Interim Chief Executive Officer; provided that, in the event the term concludes prior to the 12-month anniversary of the Effective Date for any reason other than a termination by the Company for cause or early resignation by Dr. Smith, no fewer than 1,000,000 of the restricted stock units subject to the Additional RSU Award will vest. Any unvested portions of the Interim CEO RSU Award and the Additional RSU Award will vest upon a change of control of the Company (as defined in Merlin, Inc.’s 2026 Incentive Award Plan (the “LTIP”)). The Interim CEO RSU Award and the Additional RSU Award will be granted under and subject to the terms and conditions of the LTIP.
During his term as Interim Chief Executive Officer, Dr. Smith will be eligible for benefits consistent with those of senior management and reimbursement of reasonable business expenses under Company policies, including temporary housing near the Company’s headquarters. Dr. Smith will not be eligible to participate in the Severance Plan or any similar Company plan or policy. After his service as Interim Chief Executive Officer ends, he will be compensated under the applicable non-employee director compensation program for so long as he continues to serve as a director.
The foregoing summary is qualified in its entirety by reference to the Offer Letter, which is attached as Exhibit 10.2 to this current report on Form 8-K and which is incorporated by reference into this Item 5.02, will be filed as an exhibit to the Company’s Form 10-K for the fiscal year ending December 31, 2026.
Item 8.01. Other Events.
On November 19, 2026, the Company issued a press release announcing an executive leadership change, a copy of which is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| | | | | |
| Exhibit No. | Description |
| 10.1 | |
| 10.2 | |
| 99.1 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| Date: November 19, 2026 | MERLIN, INC. |
| By: | /s/ Leslie Ravestein |
| Name: | Leslie Ravestein |
| Title: | Chief Legal Officer and Secretary |